GTBP Key Statistics, Chart & Performance
The current stock price of GTBP is 0.7559 USD. In the past month the price increased by 21.31%. In the past year, price decreased by -70.59%.
GTBP Latest News, Press Relases and Analysis
GTBP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.74 | 396.55B | ||
| AMGN | AMGEN INC | 15.47 | 182.20B | ||
| GILD | GILEAD SCIENCES INC | 15.13 | 153.73B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.95 | 109.90B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.49 | 77.98B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 911.63 | 61.42B | ||
| INSM | INSMED INC | N/A | 44.06B | ||
| NTRA | NATERA INC | N/A | 32.66B | ||
| BIIB | BIOGEN INC | 10.76 | 26.43B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.97 | 20.42B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.20B |
Related stock screener links
About GTBP
Company Profile
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The company is headquartered in San Francisco, California and currently employs 1 full-time employees. The company went IPO on 2013-10-22. The firm is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The firm also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.
Company Info
GT BIOPHARMA INC
505 Montgomery Street, 10Th Floor
San Francisco CALIFORNIA 90212 US
CEO: Anthony J. Cataldo
Employees: 1
Phone: 18003049888
GT BIOPHARMA INC / GTBP FAQ
What does GTBP do?
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The company is headquartered in San Francisco, California and currently employs 1 full-time employees. The company went IPO on 2013-10-22. The firm is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The firm also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.
Can you provide the latest stock price for GT BIOPHARMA INC?
The current stock price of GTBP is 0.7559 USD. The price decreased by -3.1% in the last trading session.
Does GT BIOPHARMA INC pay dividends?
GTBP does not pay a dividend.
What is the ChartMill technical and fundamental rating of GTBP stock?
GTBP has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Where is GT BIOPHARMA INC (GTBP) stock traded?
GTBP stock is listed on the Nasdaq exchange.
Can you provide the PE ratio for GTBP stock?
GT BIOPHARMA INC (GTBP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.79).
GTBP Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to GTBP. When comparing the yearly performance of all stocks, GTBP is a bad performer in the overall market: 94.3% of all stocks are doing better.
GTBP Financial Highlights
Over the last trailing twelve months GTBP reported a non-GAAP Earnings per Share(EPS) of -5.79. The EPS increased by 71.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -439.13% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
GTBP Forecast & Estimates
7 analysts have analysed GTBP and the average price target is 8.16 USD. This implies a price increase of 979.51% is expected in the next year compared to the current price of 0.7559.